Monday, November 16, 2026
CN
  • About
  • Advertise
  • Careers
  • Contact
Money Compass
  • Home
  • Financial News
  • Investment News
  • Other News
    • Bursa News
    • Government News
    • Listing Companies News
    • Oversea Financial & Investment News
  • Interviews
    • Features Interviews
    • Corporate Interviews
  • Financial & Investment Articles
  • PR Newswire
  • Login
No Result
View All Result
Money Compass
Home PR Newswire

Roche Diagnostics Makes Endotrophin Research Prototype Assay Available at Nordic Bioscience

Money Compass by Money Compass
November 16, 2026
in PR Newswire
0
Roche Diagnostics Makes Endotrophin Research Prototype Assay Available at Nordic Bioscience
1
SHARES
100
VIEWS
Share on FacebookShare on Twitter

HERLEV, Denmark, Nov. 16, 2026 /PRNewswire/ — Nordic Bioscience is pleased to announce that Roche Diagnostics is making its Endotrophin (ETP) research prototype assay available on its cobas® e801 Analyzers at Nordic Bioscience’s CLIA lab.

Roche cobas® e 801 analyzer at Nordic Bioscience's laboratory, where Roche Diagnostics is making its Endotrophin (ETP) research prototype assay available.
Roche cobas® e 801 analyzer at Nordic Bioscience’s laboratory, where Roche Diagnostics is making its Endotrophin (ETP) research prototype assay available.

Related posts

ZTE Powers High Efficiency AIDC with Robust Energy Infrastructure

ZTE Powers High Efficiency AIDC with Robust Energy Infrastructure

November 16, 2026
Ampang Puteri Specialist Hospital Launches KPJ Healthcare’s First Dedicated International Patient Ward

Ampang Puteri Specialist Hospital Launches KPJ Healthcare’s First Dedicated International Patient Ward

November 16, 2026

The Endotrophin assay is a sandwich immunoassay that quantifies the intact 77-amino-acid Endotrophin hormone – the signaling pro-peptide released during formation of type VI collagen. Endotrophin is associated with fibrosis, inflammation and adverse outcomes across cardiovascular, kidney and metabolic disease.

Endotrophin is the second biomarker from the collaboration between Nordic Bioscience and Roche Diagnostics to reach the Roche platform, following the launch of Elecsys® PRO-C3, which is available as a CE-marked test.

Endotrophin has been measured in more than 50,000 patients with cardio-kidney-metabolic disease. Elevated Endotrophin levels have been associated with mortality and adverse outcomes in heart failure with preserved ejection fraction (HFpEF), and the FDA has issued a letter of support for the continued research of Endotrophin as a trial enrichment tool in HFpEF. Endotrophin captures fibroinflammatory risk beyond PREVENT and NT-proBNP[1]. In chronic kidney disease, Endotrophin levels are markedly increased with increasing disease activity; high levels predict eGFR decline, and changes in Endotrophin track changes in kidney function.

Endotrophin is more than a risk marker. Mendelian randomization studies link Endotrophin causally to coronary artery disease, knock-out models show protection against kidney fibrosis and loss of kidney function, and CD44 has been identified as the Endotrophin receptor.

“Endotrophin may be the best biomarker for the cardio-renal syndrome – but more importantly, it is more than a biomarker. It is a target to treat. We see it as a new TNF-alpha story,” said Morten Karsdal, CEO of Nordic Bioscience.

Reference

[1] Yoshiji S, Osawa I, Hill JA, Scherer PE, Audoly L. Adipokine Axis in Heart Failure: Endotrophin Captures Fibroinflammatory Risk Beyond PREVENT and NT-proBNP in Adults with Obesity. Circulation. 2026. AHA Scientific Sessions 2026, Abstract 6394.

https://doi.org/10.1161/CIRC.154.SUPPL_1.6394 

About Nordic Bioscience

Nordic Bioscience is a Danish biomarker company headquartered in Herlev, Denmark. We are engaged in biomarker development focusing on the Extracellular Matrix (ECM) using our unique neoepitope platform technology. We combine our expertise in biomarker development with preclinical and clinical research. This enables us to develop biomarkers that provide fast and objective decision-making for compound selection and development in clinical trials as well as provide value for patients in a diagnostic setting. For more information about Nordic Bioscience, visit us at https://www.nordicbioscience.com 

​ 

Previous Post

ROBOTERA Launches XHAND 1 Pro-U, Featured in NVIDIA’s GR00T 2 DexUMI Demonstration

Next Post

Ampang Puteri Specialist Hospital Launches KPJ Healthcare’s First Dedicated International Patient Ward

Next Post
Ampang Puteri Specialist Hospital Launches KPJ Healthcare’s First Dedicated International Patient Ward

Ampang Puteri Specialist Hospital Launches KPJ Healthcare's First Dedicated International Patient Ward

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

BROWSE BY CATEGORIES

  • Blog
  • Bursa News
  • Corporate Interviews
  • Features Interviews
  • Financial & Investment Articles
  • Financial News
  • Government News
  • Investment News
  • Listing Companies News
  • Oversea Financial & Investment News
  • PR Newswire

BROWSE BY TOPICS

2018 League Balinese Culture Bali United Budget Travel business Champions League Chopper Bike Doctor Terawan industrial Istana Negara Malaysia Market Stories National Exam net zero emissions targets 2025 Renewable energy Visit Bali

Recent News

  • ZTE Powers High Efficiency AIDC with Robust Energy Infrastructure
  • Ampang Puteri Specialist Hospital Launches KPJ Healthcare’s First Dedicated International Patient Ward
  • Ampang Puteri Specialist Hospital Launches KPJ Healthcare’s First Dedicated International Patient Ward

Category

  • Blog
  • Bursa News
  • Corporate Interviews
  • Features Interviews
  • Financial & Investment Articles
  • Financial News
  • Government News
  • Investment News
  • Listing Companies News
  • Oversea Financial & Investment News
  • PR Newswire
  • About
  • Advertise
  • Careers
  • Contact

Copyright © 2024 Money Compass Media (M) Sdn Bhd. All Rights Reserved

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Home
  • Features Interviews
  • Government News
  • Financial News
  • Investment News
  • Listing Companies News
  • Corporate Interviews
  • Bursa News
  • Financial & Investment Articles
  • Oversea Financial & Investment News

Copyright © 2024 Money Compass Media (M) Sdn Bhd. All Rights Reserved